1Zhou HH,Genetic polymorphism of CYP2c19 in Chinese ethnic populations[J]. International Congress Series, 2002,1244: 51 61 .
2SimSO,aisingerC,DahlML,et aI.A common novel CYP2CI9 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants[J]. Ciin Pharmacol Ther, 2006,79(1): 105-113.
4He N,Yan FX,Huang 8L,et aI.CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Ohinese Dai population[J].Eur J Clin Pharmacol,2002,58:15-18.
8Uno T,Niioka T,Hayakari M,et al. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations[J]. Eur J Clin Pharrnacol, 2007,63: 143-149.
9Brandt JT,Kirkwood S,Mukhopadhay N,et al .CYP2019*2 polymorphism contributes to a diminished pharmacodynamic response to clopidogrel[J]. J Am Colt Cardiol,2006,47:380A.
10Sofi F, Giusti B, Marcucci FL, et al. Cytochrome P450 2019(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel : a meta-analysis[J]. Pharmacogenomics J, 2011,11 . 199-206.
4Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C19:correlation between 2C19 and S-mephenytoin 4'-hydroxylation[ J ]. Arch Biochem Biophys, 1993,306(1):240 - 5.
5Dojo M,Azuma T,Saito T,et al. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor ( omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan [J].Dig Liver Dis, 2001,3
6Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor,amoxicillin, and clarithromycin [ J ]. Clin Pharmacol Ther,2001,69(3) :158 -6
7De Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of Smephenytoin metabolism in humans [ J ]. J Biol Chem,1994,269 (22): 15419 - 22.
8De Morais SM, Wilkinson GR, Blaisdell J, et al.Identification of a new genetic defect responsible for the polymorphism of (S)- mephenytoin metabolism in Japanese[ J]. Mol P harmacol, 1994,46(4) :594 - 8.
9Ishizaki T, Horai Y. Review article: cytochrome P450 and the metalolism of proton pump inhibitors- emphasis on rabeprazole[ J ]. Aliment Pharmacol Ther, 1999, 13 ( suppl3) :27 -36.
10Saitoh T, Fukushima Y, Otsuka H, et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers [ J ]. Aliment Pharmacol Ther,2002, 16 (10): 1811 - 7.
